| Followers | 225 |
| Posts | 13194 |
| Boards Moderated | 0 |
| Alias Born | 09/26/2011 |
Monday, April 17, 2017 5:09:43 PM
Restated Certificate of Incorporation effecting a reverse stock split of outstanding Cerulean common stock at a ratio ranging from 1: to 1: as determined by the Cerulean board of directors and agreed to by Daré; and approve the adjournment of the special meeting by Cerulean’s board of directors, in its discretion, if necessary, to solicit additional proxies to approve the other proposals, each as described in the accompanying proxy statement.
Recent DARE News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 08:25:47 PM
- Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies • GlobeNewswire Inc. • 05/18/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:03:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:01:25 PM
- Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2026 08:01:00 PM
- Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:11:05 PM
- Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026 • GlobeNewswire Inc. • 05/07/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 08:40:46 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:33:21 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:02:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 01:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 08:07:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 08:10:22 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 08:58:43 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 04/02/2026 04:15:02 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:02:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:01:23 PM
- Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/26/2026 08:01:00 PM
- On National Viagra Day, Women Finally Claim Their Turn: • GlobeNewswire Inc. • 03/23/2026 12:00:00 PM
- Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 • GlobeNewswire Inc. • 03/20/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 08:37:30 PM
- Dare Bioscience secures NIH funding extension for preterm birth therapy • IH Market News • 03/16/2026 02:29:18 PM
- Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth • GlobeNewswire Inc. • 03/16/2026 12:00:00 PM
